Welcome to our dedicated page for PACS Group SEC filings (Ticker: PACS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PACS Group's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PACS Group's regulatory disclosures and financial reporting.
PACS Group, Inc. President & COO Joshua Jergensen reported three open-market sales totaling 40,000 shares of common stock on July 15, 2026. The shares were sold at weighted average prices between $43.74 and $45.78 per share under a Rule 10b5-1 trading plan adopted March 12, 2026. The transactions were reported as sales of stock held in his direct ownership, and he continues to hold PACS Group common stock afterward.
PACS Group, Inc. director and ten percent owner Mark Hancock reported open-market sales of 13,628 shares of common stock on July 14 and 15, 2026. The shares were sold at weighted average prices of $45.0350 and $45.0525 per share under a Rule 10b5-1 trading plan adopted on March 11, 2026. Following these transactions, Hancock directly holds 53,906,884 shares of PACS Group common stock.
Mark Hancock, a shareholder of PACS, has submitted a notice under Rule 144 covering the planned sale of 15,827,237 common shares through Citigroup Global Markets Inc on the NYSE, with an aggregate market value of 150114.93 and an approximate sale date of July 15, 2026.
Hancock acquired 54,626,199 common shares for cash from the issuer at its formation on March 1, 2023. Over the past three months, he has reported multiple block sales of common stock, including 153,254 shares on June 15, 2026 for 5568759.95 and 83,066 shares on June 16, 2026 for 2982385.05.
A Form 144 notice for PACS reports that Mark Hancock plans to sell 10,296 shares of PACS common stock through Citigroup Global Markets Inc. The planned sale has an aggregate market value of $463,680.36, with the shares listed on the NYSE and an approximate sale date of 07/14/2026. The notice also states that there are 15,827,237 shares of this class outstanding.
The common shares being sold were originally acquired on 03/01/2023 as part of the formation of the issuer, for cash. The Form 144 disclosure lists multiple PACS common stock sales by Mark Hancock over the prior three months, including transactions such as 153,254 shares sold on 06/15/2026 and 142,163 shares sold on 07/06/2026 for multi‑million dollar proceeds.
PACS Group, Inc. director and ten-percent owner Mark Hancock reported open-market sales of common stock totaling 25,304 shares on July 8–9, 2026, at weighted average prices of about $45 per share. After these transactions, he directly holds more than 53.9 million shares of PACS Group common stock. The sales were effected pursuant to a Rule 10b5-1 trading plan and were executed in multiple trades within disclosed price ranges.
Mark Hancock reported multiple sales of Common stock of PACS via Form 144, listing specific transactions between 06/15/2026 and 07/08/2026. The filing lists individual trades with share counts and gross proceeds, including notable sales of 153,254 shares for $5,568,759.95 and 142,163 shares for $6,444,860.09.
The notice names Citigroup Global Markets Inc. as the broker and records multiple cash sales on discrete dates. The filing is a resale disclosure of transactions by a single holder; cash‑flow treatment and any post‑transaction holdings are not stated in the provided excerpt.
PACS reported proposed sales under Rule 144 via a Form 144 notice. The filing lists an issuer-origin acquisition of 54,626,199 shares on 03/01/2023 and multiple sales by Mark Hancock between 06/15/2026 and 07/06/2026, with individual transactions and cash amounts shown. The notice identifies Citigroup Global Markets Inc as the broker and NYSE as the market.
PACS Group, Inc. Chief Accounting Officer Michelle Renee Lewis reported selling a total of 15,000 shares of common stock in three open-market transactions at weighted average prices around $45 per share. These sales were made pursuant to a Rule 10b5-1 trading plan adopted on March 3, 2026, and she continues to hold 355,338 shares directly after the transactions.
PACS Group director and ten percent owner Mark Hancock reported a mix of stock sales and a new equity award. On July 6, 2026, he sold 142,163 shares of common stock at a weighted average price of $45.3343 per share. He also sold 12,825 shares on July 2, 2026 at $45.0129 and 6,080 shares on July 1, 2026 at $45.0191, all as open-market transactions under a pre-arranged Rule 10b5-1 trading plan.
Following these trades, Hancock directly held 53,945,816 shares of PACS Group common stock. Separately, on July 1, 2026 he received 4,287 restricted stock units, each convertible into one share of common stock, vesting 100% on the earlier of July 1, 2027 or the next annual meeting, subject to his continued service.